Mode
Text Size
Log in / Sign up
N/A N=1,493

Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients

Arthritis, Rheumatoid

Enrolled (actual)
1,493
Serious AEs
Results posted
Sep 2021
Primary outcome: Primary: Disease Activity Score 28 (DAS28) in Participants With Positive Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12) — 3.13; 3.1 units on a scale

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Enbrel (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Pfizer
Primary completion
Aug 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Disease Activity Score 28 (DAS28) in Participants With Positive Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12)
3.13; 3.1
PRIMARY
Clinical Disease Activity Index (CDAI) Score in Participants With Positive Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12)
8.0; 8.2
PRIMARY
Disease Activity Score 28 (DAS28) in Participants With Negative Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12)
3.10; 3.16
PRIMARY
Clinical Disease Activity Index (CDAI) Score in Participants With Negative Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (ACCP) at Last Follow-up Visit (Month 12)
7.3; 6.8

Summary

This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic citrullinated peptide using data from the Baghdad Teaching Hospital registry.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed RA patients.

-≥18 years of age

  • Did not receive previous another biological treatment

Exclusion Criteria

  • Had previous biological treatment
  • Use of etanercept for less than 1 year
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04428424). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search